Understanding the Role of Genes in the Blood Clotting Process in Children With Acute Lung Injury
Acute lung injury (ALI) is a severe lung condition that causes respiratory failure. This study will examine if differences in genes involved in the blood clotting process may affect the severity of and recovery from ALI in children hospitalized with the condition.
Respiratory Distress Syndrome, Adult
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Targeted Genomic Analysis of Coagulation Pathways in Acute Lung Injury|
- Number of ventilator-free days [ Time Frame: Measured during participant's hospital stay ] [ Designated as safety issue: No ]
- Mortality and organ dysfunction [ Time Frame: Measured during participant's hospital stay ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Blood and plasma samples will be analyzed
|Study Start Date:||November 2007|
|Estimated Study Completion Date:||December 2013|
|Estimated Primary Completion Date:||December 2013 (Final data collection date for primary outcome measure)|
ALI is a life-threatening condition that involves inflammation of the lungs and fluid accumulation in the air sacs, which leads to low blood oxygen levels and respiratory failure. Common causes include pneumonia, sepsis, and lung trauma. Symptoms, including breathing difficulty, low blood pressure, and organ failure, usually develop within 24 to 48 hours of the original injury or illness. Most patients require immediate care in an intensive care unit, and the main form of treatment is mechanical ventilation, which delivers oxygen and a continuous level of pressure to the damaged lungs. Although progress has been made in understanding how ALI develops, it is still unknown why recovery outcomes differ among people. Differences in the genetic basis of protein C and fibrinolysis pathways, which both play a role in preventing blood clots, may be a factor in determining the severity of and recovery from ALI. The purpose of this study is to analyze DNA from children with ALI to identify genetic variations that affect the blood clotting pathways.
This study will enroll children who are hospitalized with ALI. Participants' medical records will be reviewed to gather information about symptoms, physical exam findings, mechanical ventilator settings, and laboratory test results. A blood collection will occur on Days 1 and 3. Study researchers will use high throughput DNA sequencing technology to analyze participants' DNA.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00605527
|Contact: Anil Sapru, MD, MASemail@example.com|
|United States, California|
|University of California, San Francisco||Recruiting|
|San Francisco, California, United States, 94143|
|Contact: Anil Sapru, MD, MAS 415-476-0963 firstname.lastname@example.org|
|Principal Investigator:||Anil Sapru, MD, MAS||University of California, San Francisco|